Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB-206
- Development stage
- Preclinical
- Lead developer
- Dewcell Biotherapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
DCB-206 is an investigational cell therapy candidate developed by Dewcell Biotherapeutics, designed as an artificial platelet product for use in blood transfusion and regenerative medicine. The therapy is likely produced using Dewcell's proprietary platform technologies, such as en-aPLT™ (engineered artificial platelet production platform) or i-aPLP™ (iPSC-derived artificial platelet-like particle), which aim to generate functional, scalable, and donor-independent platelet substitutes. DCB-206 is intended to mimic the physiological role of natural platelets in hemostasis and wound healing, providing a therapeutic option for patients requiring platelet transfusions or regenerative treatments to support tissue repair.
Beyond the preview
Go deeper on DCB-206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB-206.